WELCOME to epgonline.org
Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
Added 6 hours ago Drug news
Subgroup analysis of FLAURA data of Tagrisso in NSCLC shows specific patient group benefits
Added 6 hours ago Drug news
A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) has been published in Circulation accoridng to Janssen Pharma.
Posted 1 month ago
An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?
Posted 5 months ago
Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.
Posted 6 months ago
It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.
Posted 7 months ago
Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?
When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available.
Added 2 days ago
Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.
Background: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk...
Added 2 days ago
Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole.
Added 3 days ago
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and longterm treatment of mixed states in bipolar disorder
This WFSBP guideline has been developed to supply a systematic overview of all scientific evidence pertaining to the acute and longterm treatment of bipolar mixed states in adults.
Added 11 days ago
Evidence shows that rectal cancer is distinct from colon cancer, with different aetiologies and risk factors possibly reflecting different environmental exposures.
Added 4 years ago
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management...
Added 5 years ago
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)
This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...
Added 6 days ago
A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)
This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Added 10 days ago
The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.
Added 1 month ago